Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying

Viking Therapeutics (VKTX) is advancing its weight-loss candidate VK2735 in Phase 3, with an oral Phase 3 study slated to begin in Q4 and additional maintenance-dosing data expected in Q3. The article notes potential upside if trial updates stay positive, citing that the stock jumped more than 100% after strong Phase 2 data in Feb 2024, but also flags competitive risk versus Eli Lilly and Novo Nordisk and the possibility of stagnation despite a 40% gain over the past year. Overall, the piece argues for room to run (target discussed: ~$50) contingent on continued positive clinical and pipeline progress.

Analysis

VKTX is still a binary-duration story, not a fundamentals story yet. The stock’s main torque comes from re-rating optionality: each credible de-risking event can pull forward an acquisition or launch narrative, while any tolerability or efficacy miss quickly exposes the gap between a pre-revenue asset and the commercial scale needed to challenge entrenched obesity leaders. The market is likely underestimating how fast sentiment can swing in either direction around the next 1-2 readouts, but it is also likely overestimating how much near-term data alone can justify a durable $50+ valuation without proof of differentiation versus the incumbents.

On competitive dynamics, a positive VKTX signal is more likely to pressure the broader obesity development cohort than LLY or NVO. The established players have the manufacturing, formulary access, and sales infrastructure to absorb modest share leakage; the vulnerable names are the smaller, earlier-stage programs whose valuation is mostly scarcity value. If VKTX demonstrates a cleaner convenience/safety profile, the real second-order effect is not immediate share capture, but a higher probability that large pharma uses M&A to preempt pipeline erosion, which could lift takeover expectations across the obesity complex for 1-3 months.

The contrarian view is that consensus may be confusing ‘room in the market’ with ‘room for this stock.’ In obesity, the right question is not whether demand is large, but whether the company can earn a better growth multiple than the market is already paying for optionality. A failed maintenance or oral transition would likely compress the stock sharply over days, while a clean data set could extend the move over months; the falsifier is any evidence VK2735 is materially inferior on durability, GI tolerability, or convenience versus the market leaders.

Key Decisions for Investors

• Long VKTX only as an event-driven volatility expression into the next maintenance/phase 3 data window; prefer a call spread structure over common stock to cap downside from a binary miss and preserve upside if the market re-rates takeover odds.
• If positioning for a 1-3 month catalyst path, set a conditional add only after a clean data readout with no safety flags; below that, the stock is still trading as if success is assumed, so chasing before data offers poor risk/reward.
• Avoid a direct short in LLY or NVO as a hedge: the incumbents are more likely to absorb VKTX success than lose it, so their share price sensitivity to a VKTX update is limited; better to hedge obesity beta at the portfolio level if available.
• Watch for any announcement of a partnership or M&A interest as the highest-upside catalyst; if that emerges, the trade becomes a sentiment squeeze rather than a pure clinical de-risking story, and the market can overshoot rapidly.